A Comprehensive Monograph on Probenecid (DB01032): Pharmacology, Clinical Utility, and Safety Profile

Executive Summary

Probenecid is a small molecule drug classified as a prototypical uricosuric and renal tubular blocking agent. A sulfonamide derivative, its development was initially driven by the need to extend the therapeutic efficacy of limited penicillin supplies during World War II by inhibiting the antibiotic's renal excretion.[1] This dual-action profile defines its modern clinical utility. Probenecid is primarily indicated for the long-term management of hyperuricemia associated with chronic gout and gouty arthritis, where it promotes the excretion of uric acid.[3] Concurrently, it serves as an adjuvant to therapy with certain β-lactam antibiotics and other medications, elevating their plasma concentrations to enhance therapeutic effects.[5] The pharmacological basis for these actions is its competitive inhibition of organic anion transporters (OATs) in the renal tubules, which simultaneously blocks the reabsorption of urate and the secretion of various acidic drugs.[7] While effective, its use is complicated by a significant potential for drug-drug interactions stemming from this mechanism and a notable risk of promoting uric acid nephrolithiasis, which necessitates specific patient management strategies.[2] This report provides a comprehensive examination of Probenecid's chemical properties, pharmacological profile, clinical applications, and safety considerations.

Chemical Identity and Physicochemical Properties

The precise identification and characterization of Probenecid's chemical and physical properties are fundamental to understanding its formulation, biological activity, and disposition within the body.

Nomenclature and Identifiers

Probenecid is recognized across scientific and regulatory domains by a variety of names and unique identifiers.

• IUPAC Name: 4-(dipropylsulfamoyl)benzoic acid [1]
• Common Synonyms: p-(Dipropylsulfamoyl)benzoic acid, 4-((Dipropylamino)sulfonyl)benzoic acid, Probenecid acid, Benemid [7]
• Key Identifiers:
• CAS Number: 57-66-9 [2]
• DrugBank ID: DB01032 [2]
• PubChem CID: 4911 [2]
• UNII: PO572Z7917 [2]
• KEGG: D00475 [2]

Chemical Structure and Formula

The molecular structure of Probenecid consists of a benzoic acid core substituted with a dipropylsulfamoyl group, which dictates its chemical behavior and biological interactions.

• Molecular Formula: C13​H19​NO4​S [7]
• Molecular Weight:
• Average: 285.36 g/mol [2]
• Monoisotopic: 285.103478791 Da [7]
• Structural Representations:
• SMILES: CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(=O)O [1]
• InChI: InChI=1S/C13H19NO4S/c1-3-9-14(10-4-2)19(17,18)12-7-5-11(6-8-12)13(15)16/h5-8H,3-4,9-10H2,1-2H3,(H,15,16) [1]
• InChIKey: DBABZHXKTCFAPX-UHFFFAOYSA-N [1]

Physicochemical Properties

The physical characteristics of Probenecid are summarized in Table 1. These properties directly influence its pharmacokinetic profile and inform clinical guidelines for its administration.

Table 1: Summary of Physicochemical Properties of Probenecid

Property	Value	Source(s)
IUPAC Name	4-(dipropylsulfamoyl)benzoic acid	1
Molecular Formula	C13​H19​NO4​S	7
Average Molecular Weight	285.36 g/mol	2
Appearance	White or nearly white, fine crystalline powder	1
Melting Point	194–200 °C	1
Water Solubility	Practically insoluble (<0.1 g/100 mL at 20 °C)	1
Solubility in other solvents	Soluble in dilute alkali, alcohol, chloroform, acetone	1
Partition Coefficient (LogP)	3.21	1
pKa	5.8 (at 25 °C)	10

The physicochemical properties of Probenecid are direct determinants of its clinical behavior. As a weak acid with a pKa of 5.8, its ionization state is pH-dependent.[10] Its structure combines a lipophilic dipropylsulfamoyl moiety with a polar carboxylic acid group, resulting in very low aqueous solubility ("practically insoluble") but high lipid solubility, as indicated by a LogP of 3.21.[1] This high lipophilicity facilitates its complete absorption from the gastrointestinal tract following oral administration and allows it to readily cross cellular membranes to interact with its intracellular transporter targets.[13] Conversely, its poor water solubility is the direct cause of its primary renal-related adverse effect: the potential for crystallization within the acidic environment of the renal tubules. This risk underpins the critical clinical recommendations for patients to maintain a liberal fluid intake and alkalinize their urine to prevent the formation of both uric acid and drug-related kidney stones.[15] The presence of the carboxylic acid group allows for the formation of a more water-soluble sodium salt, a key consideration for pharmaceutical formulation.[1]

Comprehensive Pharmacological Profile

Probenecid's therapeutic effects and its extensive interaction profile are rooted in its ability to competitively inhibit specific transport proteins, primarily within the kidneys.

Mechanism of Action

Probenecid's clinical actions arise from three distinct, yet related, mechanisms.

Primary Uricosuric Effect

Probenecid is the archetypal uricosuric agent. It functions by competitively inhibiting the reabsorption of urate from the glomerular filtrate at the proximal convoluted tubule of the kidney.[7] This action increases the urinary excretion of uric acid, thereby lowering serum urate concentrations.[7] The principal molecular targets for this effect are renal anion transporters, most notably Urate Transporter 1 (URAT1) and Organic Anion Transporter 1 (OAT1).[8] It also demonstrates inhibitory activity against other key transporters in this family, including OAT3 and OAT4 (solute carrier family 22 members 11).[7] By competing with uric acid for binding sites on these transporters, Probenecid effectively prevents urate from being transported back into the bloodstream, promoting its elimination.

Renal Tubular Blocking Effect (The "Penicillin Effect")

The same fundamental mechanism of action—competitive inhibition of organic anion transporters—is responsible for Probenecid's ability to block the renal tubular secretion of numerous weak organic acids.[6] This was the original therapeutic goal for its development, as it was used to inhibit the rapid renal clearance of penicillin during World War II, thereby increasing the antibiotic's plasma concentration and prolonging its therapeutic effect from limited supplies.[2] This action is not specific to penicillin and applies to a broad range of drugs that are substrates for OATs, including most penicillins, many cephalosporins, certain antivirals (e.g., cidofovir), and chemotherapeutics (e.g., methotrexate).[2] This single molecular action is thus responsible for both a primary therapeutic indication (as an antibiotic adjuvant) and the drug's most clinically significant and dangerous interactions.

Novel Mechanisms: Pannexin 1 Inhibition

More recent investigations have revealed that Probenecid is a potent inhibitor of pannexin 1 (Panx1) channels.[2] This discovery suggests a more complex mechanism of action in gout than previously understood. Gout is not merely a condition of hyperuricemia but a profoundly inflammatory disease triggered by urate crystals. Panx1 channels are integral to the inflammatory cascade; their activation leads to the release of ATP, which acts as a "danger signal" to activate the NLRP3 inflammasome. This, in turn, promotes the release of the potent pro-inflammatory cytokine interleukin-1β (

IL−1β), a central mediator of acute gouty inflammation.[2] By blocking Panx1 channels, Probenecid may directly dampen this inflammatory response. This suggests that Probenecid may not only act over the long term by removing the urate trigger but may also possess direct anti-inflammatory properties, reframing it from a simple uricosuric agent to a potential disease-modifying drug with a dual mechanism of action.

Pharmacodynamics

The pharmacodynamic effects of Probenecid are a direct consequence of its mechanisms of action. By promoting sustained uricosuria, it reduces the total miscible urate pool in the body.[7] This effect slows the deposition of new monosodium urate crystals in joints and soft tissues and encourages the gradual resorption of established tophi.[6] For co-administered drugs that are OAT substrates, the pharmacodynamic effect is a dose-dependent increase in plasma concentration and a prolongation of the elimination half-life. This can be therapeutically beneficial, as with antibiotics, or dangerously toxic, as with methotrexate.[17]

Pharmacokinetics: Absorption, Distribution, Metabolism, and Excretion (ADME)

The disposition of Probenecid in the body follows a predictable path, though it is characterized by a clinically important non-linearity in its elimination.

Absorption

Following oral administration, Probenecid is rapidly and almost completely absorbed from the gastrointestinal tract.[13] Peak plasma concentrations are typically achieved within 2 to 4 hours of ingestion.[10]

Distribution

Probenecid is widely distributed throughout the body and is extensively bound to plasma proteins, primarily albumin, with reported binding rates of 75–95%.[2] Its high lipophilicity allows it to cross the placenta, resulting in its appearance in fetal cord blood.[21] It also crosses the blood-brain barrier, although cerebrospinal fluid (CSF) concentrations are low (approximately 2% of serum levels), suggesting the presence of an active efflux transport mechanism out of the central nervous system.[13]

Metabolism

Probenecid undergoes extensive biotransformation, primarily in the liver.[10] The main metabolic pathways include phase 1 oxidation of the N-dipropyl side chains and phase 2 conjugation of the carboxylic acid group to form an acetyl glucuronide metabolite.[14] These metabolites, particularly the glucuronide conjugate, retain some of the parent drug's uricosuric activity.[10]

Excretion

The parent drug and its metabolites are eliminated from the body primarily via the kidneys into the urine.[13] The elimination of Probenecid involves a complex renal process: it is filtered at the glomerulus, actively secreted into the proximal tubule, and then actively reabsorbed from the distal tubule.[2] Its metabolites, however, are not reabsorbed and are readily excreted.[13] The elimination half-life of Probenecid is notably dose-dependent, ranging from 4 to 12 hours.[10] This non-linear pharmacokinetic profile is a critical clinical feature. It suggests that the renal transport systems responsible for its secretion and reabsorption can become saturated at higher therapeutic doses. When this saturation occurs, a small increase in the administered dose can lead to a disproportionately large increase in plasma concentration and duration of action. This phenomenon explains why gastric intolerance is considered an early sign of overdosage and underscores the clinical guidance to titrate the dose upwards in small, cautious increments to avoid unexpected toxicity and exacerbated drug interactions.[18]

Clinical Applications and Therapeutic Efficacy

Probenecid has well-established roles in the management of gout and as an adjuvant to anti-infective therapy, along with several off-label applications.

Approved Indications

• Management of Hyperuricemia in Chronic Gout and Gouty Arthritis: Probenecid is indicated for the long-term reduction of serum uric acid in patients with chronic gout, particularly those with visible tophi or frequent, disabling attacks.[6] It is a prophylactic agent intended to prevent future attacks and is not effective in treating an acute gout flare. Critically, therapy should not be initiated during an acute attack.[3]
• Adjunctive Therapy for β-Lactam Antibiotics: It is approved for use as an adjuvant to elevate and prolong the plasma concentrations of penicillins (e.g., ampicillin, oxacillin) and certain cephalosporins.[5] This is employed to enhance efficacy in treating infections that require sustained high antibiotic levels, such as neurosyphilis and pelvic inflammatory disease (PID).[7]
• Adjunctive Therapy with Cidofovir: Probenecid is co-administered with the antiviral drug cidofovir to competitively inhibit its renal secretion, thereby reducing its concentration in the renal tubules and mitigating the risk of dose-limiting nephrotoxicity.[2]

Off-Label Uses

• Probenecid has been used to manage hyperuricemia induced by various other drugs, including thiazide diuretics, loop diuretics (furosemide), pyrazinamide, and ethambutol.[25]
• Due to its ability to interfere with the renal excretion of various compounds, it has been used illicitly by athletes as a masking agent to prevent the detection of performance-enhancing substances in urine drug tests.[2]

Key Clinical Considerations

A crucial aspect of Probenecid therapy is the management of paradoxical gout flares. Upon initiation, the drug can increase the frequency of acute gout attacks for the first 6 to 12 months.[3] This phenomenon is not a sign of treatment failure but rather an indicator of therapeutic effect. As Probenecid lowers serum urate levels, it creates a concentration gradient that drives the mobilization of urate crystals from long-standing deposits (tophi) in joints and tissues.[6] This rapid shift and dissolution of crystals is itself a pro-inflammatory event that can trigger an acute immune response, resulting in a flare. To manage this predictable consequence, clinical guidelines recommend the prophylactic co-administration of an anti-inflammatory agent, such as colchicine or a nonsteroidal anti-inflammatory drug (NSAID), for the first 3 to 6 months of Probenecid therapy.[13] Patient education on this point is vital to ensure adherence.

Dosage and Administration Guidelines

The safe and effective use of Probenecid requires careful adherence to indication-specific dosing, titration schedules, and important administrative practices. The information is summarized in Table 2.

Table 2: Dosage and Administration of Probenecid by Indication

Indication	Patient Population	Initial Dose	Maintenance Dose	Maximum Dose	Key Administration Notes
Chronic Gout / Hyperuricemia	Adults	250 mg orally twice daily for 1 week	500 mg orally twice daily	2–3 g/day	Titrate dose upwards in 500 mg increments every 4 weeks based on serum urate levels.
Adjunctive Antibiotic Therapy	Adults (>50 kg)	N/A	500 mg orally four times daily	2 g/day	Reduce dose in older patients with potential renal impairment.
Adjunctive Antibiotic Therapy	Pediatric (2–14 years, <50 kg)	25 mg/kg orally once	40 mg/kg/day orally in 4 divided doses	N/A	Contraindicated in children <2 years of age.

Dosing in Special Populations

• Renal Impairment: Probenecid should be used with caution in patients with renal impairment, as higher doses may be required. It is generally considered ineffective and is not recommended for use in patients with chronic renal insufficiency where the glomerular filtration rate (GFR) or creatinine clearance (CrCl) is 30 mL/minute or less.[16]

Administration

• General: To minimize gastrointestinal side effects such as nausea, Probenecid should be taken with food, milk, or antacids.[13]
• Hydration and Urine Alkalinization: To mitigate the risk of uric acid nephrolithiasis, it is imperative that patients maintain a liberal fluid intake of at least 2 liters per day.[15] Concurrently, alkalinization of the urine with agents like sodium bicarbonate (3 to 7.5 g daily) or potassium citrate (7.5 g daily) is strongly recommended, particularly during the initial phases of therapy when urate excretion is highest.[16]

Comprehensive Safety and Tolerability Profile

While generally well-tolerated, Probenecid is associated with a range of adverse effects and carries important contraindications and warnings.

Adverse Drug Reactions

• Common: The most frequently reported adverse effects are generally mild and include headache, dizziness, anorexia, nausea, vomiting, sore gums, flushing, and increased urinary frequency.[2] As previously noted, the precipitation of acute gouty attacks is common upon initiation of therapy.[9]
• Less Common: Dermatological reactions such as rash (dermatitis) and pruritus (itching) may occur.[4]
• Rare but Serious:
• Hematologic: Severe blood dyscrasias have been reported, including aplastic anemia, leukopenia, and hemolytic anemia.[15] The risk of hemolytic anemia is significantly elevated in patients with a specific pharmacogenomic predisposition: a genetic deficiency of the enzyme glucose-6-phosphate dehydrogenase (G6PD). Probenecid, as a sulfonamide derivative, can induce oxidative stress that G6PD-deficient red blood cells cannot tolerate, leading to hemolysis. This represents a critical drug-gene interaction, and caution is warranted when prescribing to individuals from populations with a high prevalence of this deficiency.[1]
• Hepatic: Cases of severe liver damage, including hepatic necrosis, have been documented.[10]
• Renal: The formation of uric acid kidney stones (nephrolithiasis) with associated renal colic is a significant risk. Nephrotic syndrome has also been reported.[9]
• Hypersensitivity: Severe allergic reactions, including life-threatening anaphylaxis, can occur, often upon re-administration of the drug after a period of discontinuation.[13]

Contraindications

Probenecid is strictly contraindicated in the following populations:

• Individuals with a known hypersensitivity to Probenecid.[22]
• Children under 2 years of age.[6]
• Patients with pre-existing blood dyscrasias or a history of uric acid kidney stones.[6]
• Initiation of therapy during an acute gout attack.[6]
• Concurrent administration of salicylates (e.g., aspirin) in any dose, as they antagonize the uricosuric effect of Probenecid.[15]

Warnings and Precautions

• Renal Impairment: Efficacy is diminished in patients with a GFR of 30 mL/min or less.[22]
• History of Peptic Ulcer: Use with caution in this population.[10]
• Pregnancy and Lactation: Probenecid crosses the placenta. Its use in pregnancy should be based on a careful risk-benefit assessment. Caution is advised during breastfeeding.[21]

Toxicity and Overdose Management

• Symptoms of Overdose: Overdose can lead to severe gastrointestinal symptoms (nausea, copious vomiting, stomach pain), central nervous system depression (stupor, confusion, coma), and tonic-clonic seizures.[13] A fatality has been reported following a massive ingestion of approximately 75 g.[30]
• Management: There is no specific antidote for Probenecid overdose. Treatment is entirely supportive. Management may involve gastric decontamination (emesis or lavage) if ingestion was recent. The primary focus is on maintaining vital functions, including respiratory support via mechanical ventilation if necessary. Seizures should be controlled with intravenous anticonvulsants such as phenobarbital or benzodiazepines.[13] Consultation with a poison control center is recommended for guidance.[3]

Significant Drug and Substance Interactions

Probenecid's mechanism of action makes it prone to a large number of clinically significant drug interactions, which are a primary safety concern.

Pharmacokinetic Interactions

The majority of interactions are pharmacokinetic, stemming from Probenecid's inhibition of renal transporters and metabolic enzymes.

Inhibition of Renal Excretion (OAT Inhibition)

Probenecid competitively inhibits the active tubular secretion of a wide array of acidic drugs, leading to increased plasma concentrations, prolonged half-lives, and a heightened risk of toxicity. Key examples include:

• Antibiotics: Penicillins, cephalosporins, and fluoroquinolones (e.g., ciprofloxacin).[2]
• Antivirals: Acyclovir, ganciclovir, oseltamivir, and zidovudine (AZT).[2]
• Chemotherapeutics: Methotrexate. This is a major interaction that can lead to severe or fatal methotrexate toxicity. Co-administration requires significant dose reduction of methotrexate and careful monitoring of serum levels.[2]
• NSAIDs: Indomethacin, naproxen, and ketorolac.[2]

Inhibition of Glucuronidation

Probenecid may also inhibit phase II glucuronidation metabolism for certain drugs:

• Benzodiazepines: Increases concentrations of lorazepam.[2]
• Analgesics: Increases concentrations of naproxen and possibly acetaminophen.[17]

Pharmacodynamic Interactions

• Salicylates (Aspirin): This is a critical contraindication. Salicylates at any dose antagonize the uricosuric effect of Probenecid, rendering it ineffective for treating gout.[6] Acetaminophen is the preferred mild analgesic for patients on Probenecid.[22]
• Alcohol: Chronic or heavy alcohol consumption can increase serum uric acid levels, potentially counteracting the effect of Probenecid and necessitating higher doses.[13]

Laboratory Test Interactions

• Probenecid can cause false-positive results for glucose in urine when using copper sulfate reduction methods (e.g., Clinitest). Tests based on the glucose oxidase method (e.g., Diastix) are unaffected and should be used instead.[6]
• It has been reported to cause falsely elevated readings for theophylline in plasma when using the Schack and Waxler analytical technique.[6]

Table 3: Clinically Significant Drug Interactions with Probenecid

Interacting Drug/Class	Mechanism of Interaction	Clinical Consequence	Management Recommendation	Severity
Salicylates (Aspirin)	Pharmacodynamic antagonism of uricosuric effect	Loss of Probenecid efficacy for gout	Contraindicated. Use acetaminophen for mild analgesia.	Major
Methotrexate	Inhibition of renal tubular secretion (OAT inhibition)	Markedly increased methotrexate levels; risk of severe or fatal toxicity	Avoid combination if possible. If necessary, reduce methotrexate dose significantly and monitor serum levels closely.	Major
β-Lactam Antibiotics	Inhibition of renal tubular secretion (OAT inhibition)	Increased plasma concentration and prolonged half-life	Often used therapeutically. Monitor for increased antibiotic-related adverse effects.	Moderate
NSAIDs (e.g., naproxen, ketorolac)	Inhibition of renal secretion and/or glucuronidation	Increased NSAID levels and risk of toxicity (GI, renal)	Use with caution. Consider lower NSAID doses and monitor for adverse effects. Ketorolac is contraindicated.	Moderate
Antivirals (e.g., acyclovir, cidofovir)	Inhibition of renal tubular secretion (OAT inhibition)	Increased antiviral levels and risk of toxicity	Used therapeutically with cidofovir to reduce nephrotoxicity. For others, consider dose reduction and monitor for toxicity.	Moderate
Lorazepam	Inhibition of glucuronidation	Increased lorazepam levels and prolonged sedation	Reduce lorazepam dose by approximately 50% and monitor for enhanced CNS depression.	Moderate
Loop Diuretics (e.g., furosemide)	Inhibition of renal tubular secretion (OAT inhibition)	Increased systemic diuretic levels but potentially reduced diuretic effect at the site of action	Monitor for reduced diuretic efficacy and titrate diuretic dose to clinical effect.	Moderate
Oral Sulfonylureas	Inhibition of renal excretion	Enhanced hypoglycemic effect	Monitor blood glucose closely. May require sulfonylurea dose reduction.	Moderate

Regulatory Status and Commercial Information

Probenecid has a long history of clinical use, which is reflected in its regulatory journey and global availability under various brand names.

Regulatory History

The regulatory history of Probenecid is complex and reflects the evolution of pharmaceutical oversight. The drug was first approved for use in the United States in 1951, prior to the 1962 Kefauver-Harris Amendment that mandated proof of efficacy.[31] A combination product with colchicine, ColBenemid, was approved in 1961 and subsequently underwent a retrospective efficacy review under the Drug Efficacy Study Implementation (DESI) program, being deemed effective in 1972.[34] Later Abbreviated New Drug Applications (ANDAs) for generic and other combination products were approved in the late 1970s, such as an ANDA from Lederle Laboratories on September 6, 1979.[35] While it remains available in the US, Probenecid is no longer licensed in the United Kingdom, though it can still be prescribed on an off-label basis.[36]

Commercial Formulations and Brand Names

• Formulation: Probenecid is commercially available as a 500 mg oral tablet.[13]
• Brand Names:
• In the United States and internationally, it has been marketed under brand names including Benemid (now discontinued in the US), Probalan, and Benuryl.[2]
• It is also available in fixed-dose combination products with colchicine, such as Colbenemid and Proben-C.[37]
• A newer combination product, Orlynvah, contains Probenecid and the antibiotic sulopenem.[38]
• Numerous other generic and international brand names exist, including Apurina, Bencid, and Prompicin.[1]

Conclusion

Probenecid remains a clinically relevant medication more than 70 years after its initial approval, occupying a unique niche as both a primary therapy for chronic gout and a valuable adjuvant for enhancing anti-infective treatments. Its utility is derived from a single, powerful pharmacological action: the competitive inhibition of renal organic anion transporters. This mechanism elegantly explains its dual therapeutic roles while also being the direct cause of its most significant limitations, namely a high propensity for clinically important drug-drug interactions and the risk of nephrolithiasis. The more recent discovery of its inhibitory effect on Pannexin 1 channels adds a new layer to its mechanism in gout, suggesting a direct anti-inflammatory role beyond simple urate lowering. Effective and safe use of Probenecid demands a thorough understanding of its non-linear pharmacokinetics, its extensive interaction profile, and the critical importance of patient counseling regarding hydration, urine alkalinization, and the management of initial gout flares. For the appropriate, well-monitored patient, Probenecid continues to be an effective and valuable therapeutic agent.

Works cited

1. Probenecid | C13H19NO4S | CID 4911 - PubChem, accessed August 19, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Probenecid
2. Probenecid - Wikipedia, accessed August 19, 2025, https://en.wikipedia.org/wiki/Probenecid
3. Probenecid: MedlinePlus Drug Information, accessed August 19, 2025, https://medlineplus.gov/druginfo/meds/a682395.html
4. Probenecid (oral route) - Side effects & dosage - Mayo Clinic, accessed August 19, 2025, https://www.mayoclinic.org/drugs-supplements/probenecid-oral-route/description/drg-20065625
5. pro-cidtm - (probenecid tablets 500 mg) 1 name of the medicine - Phebra, accessed August 19, 2025, https://www.phebra.com/wp-content/uploads/2013/10/Procid-PI-V02.pdf
6. PROBENECID tablet, film coated - DailyMed, accessed August 19, 2025, https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ab497fd8-00c3-4364-b003-b39d21fbdf38
7. Probenecid: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed August 19, 2025, https://go.drugbank.com/drugs/DB01032
8. What is the mechanism of Probenecid? - Patsnap Synapse, accessed August 19, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-probenecid
9. Probenecid: Uses, Side Effects, Alternatives & More - GoodRx, accessed August 19, 2025, https://www.goodrx.com/probenecid/what-is
10. Probenecid | 57-66-9 - ChemicalBook, accessed August 19, 2025, https://www.chemicalbook.com/ChemicalProductProperty_EN_CB9134579.htm
11. Probenecid | CAS 57-66-9 | SCBT - Santa Cruz Biotechnology, accessed August 19, 2025, https://www.scbt.com/p/probenecid-57-66-9
12. Probenecid | CAS 57-66-9 | P1726 - Spectrum Chemical, accessed August 19, 2025, https://www.spectrumchemical.com/probenecid-p1726
13. probenecid, accessed August 19, 2025, https://www.glowm.com/resources/glowm/cd/pages/drugs/p059.html
14. Probenecid, an Old Drug with Potential New Uses for Central Nervous System Disorders and Neuroinflammation - MDPI, accessed August 19, 2025, https://www.mdpi.com/2227-9059/11/6/1516
15. probenecid tablet, film coated Mylan Pharmaceuticals Inc., accessed August 19, 2025, https://s3.pgkb.org/attachment/Probenecid_02_22_19_FDA.pdf
16. Probenecid Dosage Guide + Max Dose, Adjustments - Drugs.com, accessed August 19, 2025, https://www.drugs.com/dosage/probenecid.html
17. Pharmacokinetic medicines interactions with probenecid, accessed August 19, 2025, https://www.medicinesinformation.co.nz/bulletins/pharmacokinetic-medicines-interactions-with-probenecid/
18. PROBENECID - DailyMed, accessed August 19, 2025, https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8459857e-1a52-45de-81e6-e06ce18508bb&type=display
19. Probenecid, a gout remedy, inhibits pannexin 1 channels - PMC, accessed August 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC2544448/
20. Clinical pharmacokinetics of probenecid - PubMed, accessed August 19, 2025, https://pubmed.ncbi.nlm.nih.gov/7011657/
21. Probenecid | Davis's Drug Guide for Rehabilitation Professionals - F.A. Davis AT Collection, accessed August 19, 2025, https://fadavisat.mhmedical.com/content.aspx?bookid=1873§ionid=139023176
22. Probenecid: Package Insert / Prescribing Information - Drugs.com, accessed August 19, 2025, https://www.drugs.com/pro/probenecid.html
23. Probenecid Tablets, USP500 mg Rx Only - DailyMed, accessed August 19, 2025, https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=ab497fd8-00c3-4364-b003-b39d21fbdf38&type=display
24. Colchicine/probenecid dosing, indications, interactions, adverse effects, and more, accessed August 19, 2025, https://reference.medscape.com/drug/colchicine-probenecid-999781
25. Probenecid Monograph for Professionals - Drugs.com, accessed August 19, 2025, https://www.drugs.com/monograph/probenecid.html
26. probenecid (Benemid brand no longer available) Side Effects, Dosage - MedicineNet, accessed August 19, 2025, https://www.medicinenet.com/probenecid/article.htm
27. www.ncbi.nlm.nih.gov, accessed August 19, 2025, https://www.ncbi.nlm.nih.gov/books/NBK548599/#:~:text=Common%20side%20effects%20include%20headache,life%20and%20increase%20serum%20concentrations.
28. Probenecid Uses, Side Effects & Warnings - Drugs.com, accessed August 19, 2025, https://www.drugs.com/mtm/probenecid.html
29. www.drugs.com, accessed August 19, 2025, https://www.drugs.com/pro/probenecid.html#:~:text=antibiotic%20is%20given.-,Contraindications,or%20uric%20acid%20kidney%20stones.
30. A death involving probenecid - PubMed, accessed August 19, 2025, https://pubmed.ncbi.nlm.nih.gov/1387157/
31. Probenecid - LiverTox - NCBI Bookshelf, accessed August 19, 2025, https://www.ncbi.nlm.nih.gov/books/NBK548599/
32. Oral Probenecid for Nonhospitalized Adults with Symptomatic Mild ..., accessed August 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10386418/
33. Benemid Advanced Patient Information - Drugs.com, accessed August 19, 2025, https://www.drugs.com/cons/benemid.html
34. center for drug evaluation and - accessdata.fda.gov, accessed August 19, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022353s000_SumR.pdf
35. Drug Approval Package: Probenecid NDA #086954 - accessdata.fda.gov, accessed August 19, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/anda/pre96/086954_probenecid_toc.cfm
36. Risks and wider benefits of probenecid treatment, accessed August 19, 2025, https://www.gov.je/SiteCollectionDocuments/Health%20and%20wellbeing/DRAFT%20Risks%20and%20wider%20benefits%20of%20probenecid%20treatment.pdf
37. Probenecid | Saint Luke's Health System, accessed August 19, 2025, https://www.saintlukeskc.org/health-library/probenecid
38. Probenecid - brand name list from Drugs.com, accessed August 19, 2025, https://www.drugs.com/ingredient/probenecid.html
39. Probenecid: Uses, Side Effects and Medicines | Apollo Pharmacy, accessed August 19, 2025, https://www.apollopharmacy.in/salt/Probenecid